Recombinant Human NADPH:adrenodoxin oxidoreductase, mitochondrial (FDXR)

In Stock
Code CSB-EP008575HU
Size $224
Order now
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP008575HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) FDXR.
  • Based on the SEQUEST from database of E.coli host and target protein, the LC-MS/MS Analysis result of CSB-EP008575HU could indicate that this peptide derived from E.coli-expressed Homo sapiens (Human) FDXR.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 90% as determined by SDS-PAGE.
Target Names
FDXR
Uniprot No.
Research Area
Cell Biology
Alternative Names
Adrenodoxin reductase; ADRO_HUMAN; ADXR; AR; FDXR; Ferredoxin NADP(+) reductase; Ferredoxin reductase; Ferredoxin--NADP(+) reductase; mitochondrial; NADPH adrenodoxin oxidoreductase mitochondrial; NADPH:adrenodoxin oxidoreductase
Species
Homo sapiens (Human)
Source
E.coli
Expression Region
33-451aa
Target Protein Sequence
STQEKTPQICVVGSGPAGFYTAQHLLKQHPQAHVDIYEKQPVPFGLVRFGVAPDHPEVKSYGAEDHRALEIPGEELPGVCSARAFVGWYNGLPENQELEPDLSCDTAVILGQGNVALDVARILLTPPEHLERTDITKAALGVLRQSRVKTVWLVGRRGPLQVAFTIKELREMIQLPGARPILDPVDFLGLQDKIKEVPRPRKRLTELLLRTATEKPGPAEAARQASASRAWGLRFFRSPQQVLPSPDGRRAAGVRLAVTRLEGVDEATRAVPTGDMEDLPCGLVLSSIGYKSRPVDPSVPFDSKLGVIPNVEGRVMDVPGLYCSGWVKRGPTGVIATTMTDSFLTGQMLLQDLKAGLLPSGPRPGYAAIQALLSSRGVRPVSFSDWEKLDAEEVARGQGTGKPREKLVDPQEMLRLLGH
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight
61.6kDa
Protein Length
Full Length of Mature Protein
Tag Info
N-terminal 6xHis-SUMO-tagged
Form
Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description

The preparation of this recombinant Human FDXR protein was to use gene recombination DNA technology to obtain a recombinant vector connected with a FDXR fragment (33-451aa) that could be translated into the FDXR protein and then transferred it into E.coli cells to express the recombinant FDXR protein molecule. In order to get the target protein with high purity, N-terminal 6xHis-SUMO tag was used in the production. The purity is 90% determined by SDS-PAGE.

Ferredoxin reductase (FDXR, also known as adrenodoxin reductase) is a mitochondrial flavoprotein and functions as the first electron transfer protein of mitochondrial P450 systems such as P450scc. It is a mitochondrial flavoprotein that initiates electron transport from NADPH to several cytochromes P450 via two electron carriers, ferredoxin 1 (FDX1) and FDX2. Functionally, FDXR is suggested to be involved in various metabolic processes, including steroidogenesis, heme and iron-sulfur cluster biosynthesis. Notably, recent studies have shown that FDXR mutations are associated with mitochondrial disorders, probably due to their role in iron-sulfur cluster protein biosynthesis. In addition, FDXR has also been found to be a sensitive and reliable biomarker of radiation exposure in vivo. FDXR could regulate TP73 tumor suppressor via IRP2 to modulate aging and tumor suppression. Mutation in FDXR gene is associated with Sensorial Neuropathies. Abundant FDXR expression in these steroidogenic cells was maintained through SF-1 binding to the intronic enhancer of the FDXR gene.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylation in the kidney, and sterol C-27 hydroxylation in the liver.
Gene References into Functions
  1. These data provide further insight into the pathogenic mechanism of FDXR-mediated central neuropathy, and suggest an avenue for mechanistic studies that will ultimately inform treatment. PMID: 30250212
  2. we identified a novel disease-causing gene FDXR associated with mitochondrial diseases. The biallelic FDXR mutations cause optic atrophy and neuropathy. we found that FDXR levels are significantly lower in the patient fibroblast cells with the homozygous mutations R392W. Fourteen missense or nonsense FDXR mutations were identified in this study and eight of them (I143F, V158M, T211A, I213F, K280*, R315*, C359Y, D374N) clu PMID: 29040572
  3. Using surface plasmon resonance, physiologically relevant concentrations of isatin (25-100 muM) were found to increase affinity of interactions between human recombinant ferrochelatase (FECH) and NADPH-dependent adrenodoxin reductase (ADR). PMID: 28905435
  4. Mutation in FDXR gene is associated with Sensorial Neuropathies. PMID: 28965846
  5. NOS-3 overexpression resulted in an increased sensitivity to anti-Fas induced cell death, independently of AR expression and CatD activity. PMID: 25712867
  6. These results indicated that abundant FDXR expression in these steroidogenic cells was maintained through SF-1 binding to the intronic enhancer of the FDXR gene PMID: 24321386
  7. results suggest that both FDX1 and FDX2 and their likely reductase partner, FDXR, contribute to iron-sulfur cluster biogenesis PMID: 22101253
  8. comparison of catalytic properties between conditions of limiting and saturating adrenodoxin reductase [cytochrome P450scc] PMID: 12137805
  9. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis PMID: 12370809
  10. ADXR rate of hydroxylation was linear with incubation time. PMID: 12782149

Show More

Hide All

Subcellular Location
Mitochondrion inner membrane; Peripheral membrane protein.
Protein Families
Ferredoxin--NADP reductase type 1 family
Database Links

HGNC: 3642

OMIM: 103270

KEGG: hsa:2232

STRING: 9606.ENSP00000462972

UniGene: Hs.69745

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*